HEPT

目录号: HY-10892: Data Sheet 产品使用指南
FAQs
技术支持

HEPT 是一种强效且选择性抗 HIV-1 剂。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

HEPT Chemical Structure

CAS No. : 123027-56-5

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格		是否有货
50 mg		询价
100 mg		询价
250 mg		询价

or 大包装询价

* Please select Quantity before adding items.

HEPT 相关产品

•同靶点产品:

•同靶点蛋白产品:

查看 HIV 亚型特异性产品:

查看所有亚型

HIV HIV-1 HIV-2

生物活性
纯度 & 产品资料
参考文献

生物活性

HEPT is a potent and selective anti-HIV-1 agent^[1].

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
CCRF-CEM	CC₅₀	400 μM Compound: HEPT	Cytotoxic concentration for inhibition of HTLB-IIIB replication in CEM cells. Cytotoxic concentration for inhibition of HTLB-IIIB replication in CEM cells.	[PMID: 9240351]
CCRF-CEM	CC₅₀	> 1 μM Compound: HEPT	Concentration which reduces the cell viability by 50% (CEM-SS / MT-4) Concentration which reduces the cell viability by 50% (CEM-SS / MT-4)	[PMID: 9191961]
CCRF-CEM	EC₅₀	8.3 μM Compound: HEPT	Effective concentration for inhibition of HTLB-IIIB replication in CEM cells. Effective concentration for inhibition of HTLB-IIIB replication in CEM cells.	[PMID: 9240351]
CCRF-CEM	EC₅₀	> 100 μM Compound: 5 (HEPT)	Inhibitory effect against HIV-2 replication in CEM /TK-(thymidine kinase deficient) cells. Inhibitory effect against HIV-2 replication in CEM /TK-(thymidine kinase deficient) cells.	[PMID: 7538589]
CCRF-CEM	EC₅₀	> 100 μM Compound: 5 (HEPT)	Inhibitory effect against HIV-2 replication in CEM cells. Inhibitory effect against HIV-2 replication in CEM cells.	[PMID: 7538589]
CEM-SS	IC₅₀	2 μM Compound: HEPT	Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in human T-4 lymphoblastoid cell line CEM-SS/LAI Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in human T-4 lymphoblastoid cell line CEM-SS/LAI	[PMID: 9191961]
Lymphocyte	EC₅₀	5.5 μg/mL Compound: HEPT	Concentration required to inhibit HIV-1 induced cytopathicity in human MT-4 lymphocyte cells. Concentration required to inhibit HIV-1 induced cytopathicity in human MT-4 lymphocyte cells.	[PMID: 1495006]
MT4	CC₅₀	405 μM Compound: 1, HEPT	Cytotoxicity against MT4 cells after 4 days by MTT method Cytotoxicity against MT4 cells after 4 days by MTT method	[PMID: 17095124]
MT4	CC₅₀	405 μM Compound: HEPT	Cytotoxic concentration that reduces the MT-4 cell viability by 50% Cytotoxic concentration that reduces the MT-4 cell viability by 50%	[PMID: 15149669]
MT4	CC₅₀	405 μM Compound: HEPT	Cytotoxicity against MT4 cells after 4 days by MTT method Cytotoxicity against MT4 cells after 4 days by MTT method	[PMID: 17381078]
MT4	CC₅₀	740 μM Compound: 1	Cytotoxic concentration required to reduce viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce viability of mock-infected MT-4 cells by 50%	10.1016/S0960-894X(00)80042-6
MT4	CC₅₀	740 μM Compound: 1	Concentration required to reduce viability of mock-infected MT-4 cells Concentration required to reduce viability of mock-infected MT-4 cells	[PMID: 1469700]
MT4	CC₅₀	740 μM Compound: 1; HEPT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability Cytotoxicity against human MT4 cells assessed as reduction in cell viability	[PMID: 36442370]
MT4	CC₅₀	740 μM Compound: 5e	Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 2479745]
MT4	CC₅₀	740 μM Compound: HEPT	Concentration of compound required to reduce the viability of mock-infected HIV-2 (LAV-2ROD)/MT-4 cells by 50% Concentration of compound required to reduce the viability of mock-infected HIV-2 (LAV-2ROD)/MT-4 cells by 50%	[PMID: 1732552]
MT4	CC₅₀	740 μM Compound: HEPT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 1992136]
MT4	CC₅₀	740 μM Compound: HEPT	Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells against the HIV-1 (HTLV-IIIB)induced cytopathic effect Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells against the HIV-1 (HTLV-IIIB)induced cytopathic effect	[PMID: 2016715]
MT4	CC₅₀	740 μM Compound: HEPT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 7636846]
MT4	CC₅₀	743 μM Compound: HEPT	Concentration required to reduce the viability of mock-infected MT-4 cells by 50%. Concentration required to reduce the viability of mock-infected MT-4 cells by 50%.	[PMID: 1732552]
MT4	CC₅₀	<= 399 μM Compound: HEPT	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 18692274]
MT4	CC₅₀	> 200 μg/mL Compound: HEPT	Concentration required to reduce human MT-4 cell viability by 50%. Concentration required to reduce human MT-4 cell viability by 50%.	[PMID: 1495006]
MT4	CC₅₀	> 25 μg/mL Compound: HEPT	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22652226]
MT4	CC₅₀	> 500 μM Compound: 1	Concentration of compound required to reduce the viability of mock infected MT-4 cells against HIV-1 by 50% Concentration of compound required to reduce the viability of mock infected MT-4 cells against HIV-1 by 50%	[PMID: 2016729]
MT4	CC₅₀	> 500 μM Compound: HEPT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells (HIV-1 HTLV-IIIB strain) by 50% was determined on 4th day after virus infection. Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells (HIV-1 HTLV-IIIB strain) by 50% was determined on 4th day after virus infection.	[PMID: 1992136]
MT4	EC₅₀	3.28 μM Compound: HEPT	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days	[PMID: 22652226]
MT4	EC₅₀	6.5 μM Compound: 1	Concentration of compound required to achieve 50% protection of MT-4 cells against HIV-1 virus induced cytopathic effect Concentration of compound required to achieve 50% protection of MT-4 cells against HIV-1 virus induced cytopathic effect	[PMID: 2016729]
MT4	EC₅₀	6.5 μM Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB strain) and determined on 4th day after virus infection. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB strain) and determined on 4th day after virus infection.	[PMID: 1992136]
MT4	EC₅₀	6.5 μM Compound: HEPT	Compound was evaluated for effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1 Compound was evaluated for effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1	[PMID: 7540209]
MT4	EC₅₀	7 μM Compound: 1	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1	10.1016/S0960-894X(00)80042-6
MT4	EC₅₀	7 μM Compound: 1	Effective concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-1 Effective concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-1	[PMID: 1469700]
MT4	EC₅₀	7 μM Compound: 5e	Concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1 Concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1	[PMID: 2479745]
MT4	EC₅₀	7 μM Compound: HEPT	Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1. Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1.	[PMID: 1732552]
MT4	EC₅₀	7 μM Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB). Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB).	[PMID: 1992136]
MT4	EC₅₀	7 μM Compound: HEPT	Inhibitory activity against HIV-1 (HTLV-IIIB strain) replication in MT-4 cells Inhibitory activity against HIV-1 (HTLV-IIIB strain) replication in MT-4 cells	[PMID: 2016715]
MT4	EC₅₀	7 μM Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus.	[PMID: 7636846]
MT4	EC₅₀	8.1 μM Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIRF strain) and determined on 4th day after virus infection. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIRF strain) and determined on 4th day after virus infection.	[PMID: 1992136]
MT4	EC₅₀	8.1 μM Compound: HEPT	Inhibitory activity against HIV-1 (HTLV-IIIRF strain) replication in MT-4 cells Inhibitory activity against HIV-1 (HTLV-IIIRF strain) replication in MT-4 cells	[PMID: 2016715]
MT4	EC₅₀	> 250 μM Compound: HEPT	Concentration required inhibit HIV-2 (LAV-2ROD)replication in MT-4 cells. Concentration required inhibit HIV-2 (LAV-2ROD)replication in MT-4 cells.	[PMID: 1732552]
MT4	EC₅₀	> 250 μM Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 ((LAV-2EHO strain) and determined on 4th day after virus infection. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 ((LAV-2EHO strain) and determined on 4th day after virus infection.	[PMID: 1992136]
MT4	EC₅₀	> 250 μM Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 (LAV-2ROD strain) and determined on 4th day after virus infection. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 (LAV-2ROD strain) and determined on 4th day after virus infection.	[PMID: 1992136]
MT4	EC₅₀	> 250 μM Compound: HEPT	Inhibitory activity against HIV-2(LAV-2EHO strain) replication in MT-4 cells Inhibitory activity against HIV-2(LAV-2EHO strain) replication in MT-4 cells	[PMID: 2016715]
MT4	EC₅₀	> 250 μM Compound: HEPT	Inhibitory activity against HIV-2(LAV-2ROD strain) replication in MT-4 cells Inhibitory activity against HIV-2(LAV-2ROD strain) replication in MT-4 cells	[PMID: 2016715]
MT4	IC₅₀	11 μM Compound: HEPT	Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in human T-4 lymphoblastoid cell line MT-4 IIIB Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in human T-4 lymphoblastoid cell line MT-4 IIIB	[PMID: 9191961]
MT4	IC₅₀	5.06 μM Compound: 1, HEPT	Antiviral activity against HIV1 3B in MT4 cells after 4 days by MTT method Antiviral activity against HIV1 3B in MT4 cells after 4 days by MTT method	[PMID: 17095124]
MT4	IC₅₀	5.06 μM Compound: HEPT	Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells	[PMID: 15149669]
MT4	IC₅₀	5.06 μM Compound: HEPT	Antiviral activity against wild type HIV1 3B in MT4 cells after 4 days by MTT method Antiviral activity against wild type HIV1 3B in MT4 cells after 4 days by MTT method	[PMID: 17381078]
MT4	IC₅₀	5.06 μM Compound: HEPT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 18692274]
MT4	IC₅₀	5.15 μM Compound: 35	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from cytopathic effect Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from cytopathic effect	[PMID: 24657566]
MT4	IC₅₀	> 405 μM Compound: HEPT	Inhibitory concentration against SO561945 (HIV 1 mutant RT) viral infection of MT-4 cells Inhibitory concentration against SO561945 (HIV 1 mutant RT) viral infection of MT-4 cells	[PMID: 15149669]
MT4	IC₅₀	> 405.38 μM Compound: HEPT	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 18692274]
MT4	IC₅₀	> 405.8 μM Compound: 1, HEPT	Antiviral activity against HIV2 ROD in MT4 cells after 4 days by MTT method Antiviral activity against HIV2 ROD in MT4 cells after 4 days by MTT method	[PMID: 17095124]
Vero	EC₅₀	> 100 μM Compound: 1	Antiviral activity against Vero cells, infected with HSV-1. Antiviral activity against Vero cells, infected with HSV-1.	[PMID: 1720175]
Vero	IC₅₀	> 100 μM Compound: 1	The compound was tested for toxicity in Vero cells. The compound was tested for toxicity in Vero cells.	[PMID: 1720175]

分子量

308.35

Formula

C₁₄H₁₆N₂O₄S

CAS 号

123027-56-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料

产品使用指南 (1538 KB)

参考文献

[1]. Tanaka H, et al. A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). J Med Chem. 1991 Jan;34(1):349-57. [Content Brief]

HEPT 相关分类

Infection

摩尔计算器
稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量		浓度		体积		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)	×	体积 _(start)	=	浓度 _(final)	×	体积 _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

HEPT123027-56-5HIVHuman immunodeficiency virusanti-HIV-1 agentInhibitorinhibitorinhibit

您最近查看的产品:

产品名称：

* 需求量：

* 客户姓名：

* Email：

* 电话：

* 公司或机构名称：

留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4

上海工商

沪公网安备31011502019417

沪(浦)应急管危经许[2021]201709(QFYS)

营业执照（三证合一）

HEPT

HEPT 相关产品

•同靶点产品:

•同靶点蛋白产品:

查看 HIV 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

HEPT 相关分类

摩尔计算器

稀释计算器

The molarity calculator equation

The dilution calculator equation

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

HEPT

HEPT 相关抗体

HEPT 相关产品

•同靶点产品:

•同靶点蛋白产品:

查看 HIV 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

HEPT 相关分类

摩尔计算器

稀释计算器

The molarity calculator equation

The dilution calculator equation

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z